Ampligen

Dr. William Carter, CEO of Hemispherx Biopharma, reported the Ampligen experience to a crowd of interested providers before sessions began on Saturday, January 13. He stated that since the 1980's about 1000 individuals have been treated with Ampligen, using about 80,000 doses of this experimental drug. Phase III studies have been positive—showing a 16% increase in exercise ability in treated subjects—and preliminary data has been submitted to the FDA toward the New Drug Application for Ampligen. There was no speculation when this process will be complete or when Ampligen might be available to patients.